Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial
Pal, Albiges, Tomczak, Suárez, Voss, de Velasco, Chahoud, Mochalova, Procopio, Mahammedi, Zengerling, Kim, Osawa, Angel, Gupta, Khan, Bergthold, Liu, Kalaitzidou, Huseni, Scheffold, Powles, Choueiri (2023) Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial Lancet (IF: 98.4) 402(10397) 185-195
Full text
Click the PDF icon to view the full text of the paper
Links
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11017728http://www.ncbi.nlm.nih.gov/pubmed/37290461
http://dx.doi.org/10.1016/S0140-6736(23)00922-4
